Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-Cov-2 Infection (COVID-BioVac)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- IRCCS San Raffaele
- Enrollment
- 1,100
- Locations
- 1
- Primary Endpoint
- COVID-19 vaccines response
Study Overview
Brief Summary
Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection (COVID-BioVac)
Detailed Description
The purpose of the COVID-BioVac study is to establish a biobank of biological samples from subjects who have received the anti-SARS-CoV-2 vaccine, with the ultimate aim (following approval by the EC of specific substudies) to study and characterize the antiviral immune response generated following anti-SARS-CoV-2 vaccination. To this end, the COVID-BioVac Biobank will be officially established for the collection and storage of human biological material, non-profit, to support research activities aimed at advancing scientific knowledge, including in the genetic field, on the immune response. vaccination-induced anti-SARS-CoV-2.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age ≥18 years
- •Who have vaccinated for SARS-CoV-2 with Pfizer-BioNTech vaccine or others
- •Signing of informed consent from January to March 2021
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
COVID-19 vaccines response
Time Frame: from Day 1 of first vaccination up to 1 years after the last vaccination
Create a Biobank to evaluate the immunogenicity of COVID-19 vaccines in terms of antibody titers
Secondary Outcomes
No secondary outcomes reported
Investigators
Ciceri Fabio
Principal Investigator, Professor and Head of Hematology
IRCCS San Raffaele